The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 7 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Novartis's one-time gene therapy for spinal muscular atrophy costs $2.1 million
“You know, in the case of treating a baby that had, you know, something like somatic muscular atrophy that would have otherwise died, a one and done gene therapy from Novartis, this is a therapy that's worth about, it's cost about 2.1 million dollars, effective…”
Novartis launched first FDA-approved prescription app for opioid addiction
“I mean, one example we launched in the U S a digital medicine. I mean, with paratherapeutics, this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses. And it is literally an app That has run clinic…”
Chang: Novartis acquired AAA and Endocyte to secure radioisotope supply chains
“He made two acquisitions in the radio label target oncology space. So with AAA and Endocyte being the most recent acquisition they were able to secure that supply chain for that specific radio isotope.”
Novartis spent $15 billion on gene therapy acquisitions in 2018
“We've done fifteen billion dollars of acquisitions just last year in the space, not, not including all of our internal work in each of these areas.”
Novartis employs 17,000 R&D staff and spends $9B+ annually
“We have 17,000 R&D people and spend nine, nine billion dollars plus a year in, in R&D.”